Andrew Sharples
Partner, Solicitor and European Patent Attorney
London
UPC Representative*
Andrew focuses on the life sciences and his clients ranging from start-ups to major pharmaceutical and biotech companies. His technical experience covers a range of biotechnology, pharmaceuticals, and medical devices technologies. He has also conducted patent litigation in a range of technologies, and is an expert on the complexities of FRAND.
He joined EIP after a decade in the patent group of a major international law firm. His expertise includes patent drafting and prosecution, oppositions, supplementary protection certificates and life cycle strategies. A solicitor as well as a Chartered and European patent attorney, Andrew has advised on litigious proceedings from the Patents County Court to the House of Lords, and on corporate transactions including VC investment and multi-million pound acquisitions.
Andrew has a degree in Molecular Biology from the University of Edinburgh and a master's in the Management of Intellectual Property from Queen Mary's College, University of London.
Experience
- Representing Unwired Planet in their FRAND dispute with Huawei.
- Advising Tate & Lyle on the intellectual property aspects of acquisitions of food technology companies.
- Representing Amgen in a patent infringement dispute with Hospira in relation to pegfilgrastim (Case Ref: HC09C04064nHospira, Inc. & anr v Amgen Inc.).
- Representing Bioprogress PLC in a patent entitlement dispute (Stanelco Fibre Optics Ltd v Bioprogress Technology Ltd).
- Representing Niche Generics in their patent infringement and validity action in relation to perindopril (Les Laboratories Servier v Niche Generics).
Education and qualifications
- UK Chartered Patent Attorney
- European Patent Attorney
-
1999 — 2000
MSc Management of Intellectual Property, Queen Mary College, University of London -
1994 — 1998
BSc Molecular Biology, University of Edinburgh
Career history
- 2010 — present
Partner, EIP - 2000 — 2010
Senior Associate, McDermott Will & Emery
* UPC Representatives will have the qualifications to be entitled to act as UPC Representatives when the Unified Patent Court (UPC) opens in June 2023